Exelixis, Inc. (EXEL) Provides Update On Ongoing COMET-1 Phase 3 Pivotal Trial In Men With Metastatic Castration-Resistant Prostate Cancer
3/26/2014 10:14:12 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) announced that the Independent Data Monitoring Committee (IDMC) notified the company today that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis continues to anticipate top-line data from COMET-1 in 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by